Skip to content

Studying the effect of melatonin on migraine

The effect of melatonin on reducing the frequency and intensity of migraine attacks

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190107042264N5
Enrollment
60
Registered
2022-11-02
Start date
2022-11-06
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine Headaches. Migraine

Interventions

Intervention 1: Intervention group: In both groups of patients, propranolol 20 mg twice a day is used as a standard anti-migraine treatment. In the Intervention group, 3 mg melatonin tablets (Razak co

Sponsors

Ahvaz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Confirmation of migraine according to the criteria of the International Headache Society Chronic migraine patients who are able to distinguish migraine from non-migraine headaches Patients who do not have primary internal and neurologic complaints, there is no other reason for headache in them Filling the written consent form to participate in the study at least 1 year of migraine history

Exclusion criteria

Exclusion criteria: Severe and debilitating migraine (to eliminate the therapeutic effects of excessive use of painkillers) Chronic daily headache Taking drugs other than propranolol to prevent attacks or taking sleeping pills Migraine Disability Assessment (MIDAS) Grade 4 Treatment-resistant migraine (history of unsuccessful treatment with two or more migraine drug classes) History of abnormal use of painkillers and Medication Overuse Headache Significant psychological disorders (psychological illnesses leading to chronic drug use for at least six months) Pregnancy and breastfeeding Primary medical conditions and surgeries that require medical interventions (including contraindications to beta-blockers) Presence of multiple chronic headaches other than migraine with or without medical treatment, such as tension headache History of melatonin allergy or adverse events Patient's request to withdraw from the study due to drug side effects or other reasons

Design outcomes

Primary

MeasureTime frame
Severity. Timepoint: 1, 2, 3 and 4 months after start of treatment. Method of measurement: Visual Analog Scale.;Frequency. Timepoint: 1, 2, 3 and 4 months after start of treatment. Method of measurement: Headache Diary.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAsieh Mehramiri

Ahvaz University of Medical Sciences

mehramiri.ac@gmail.com+98 61 3374 3001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 6, 2026